Do not self-treat with injections
GHK-Cu generally shows better thermal stability in aqueous solutions, while AHK-Cu may require antioxidant systems for long-term formulation stability
Certain groups should exercise particular caution or avoid BPC-157 entirely: individuals with active cancer or significant cancer history, pregnant or breastfeeding women (no safety data exists), those taking blood thinners (potential interaction effects), and anyone with autoimmune conditions affecting connective tissue

TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
Who Should Consider B12 Injections at Home
Carriers of the virus are '20% more likely to be struck down by the worlds leading killer' Human papillomavirus is spread by close contact, affecting up to 80% of people Overweight people with HPV are most at risk of heart disease, study shows HPV is the cause of thousands of cancers in men and women Government have been criticised for not providing vaccinations for boys See more Daily Mail on Google - save us as a Preferred Source Having human papillomavirus (HPV) raises women's risk of heart disease by 20 per cent, according to a study